PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsArformoterol
Arformoterol
Arformoterol, Brovana (arformoterol) is a small molecule pharmaceutical. Arformoterol was first approved as Brovana on 2006-10-06. It is used to treat bronchial spasm, chronic bronchitis, and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Arformoterol, Brovana (discontinued: Arformoterol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Arformoterol tartrate
Tradename
Company
Number
Date
Products
BROVANALupin ResearchN-021912 RX2006-10-06
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
arformoterol tartrateANDA2024-09-02
arformoterol tartrate inhalationANDA2023-01-24
arformoterol tartrate inhalation solutionANDA2024-06-26
bevespi aerosphereNew Drug Application2023-03-24
bretzriNew Drug Application2020-07-23
breynaANDA2020-09-24
breztriNew Drug Application2022-01-26
brovanaNew Drug Application2024-04-15
budesonide and formoterol fumarate dihydrateNDA authorized generic2024-10-22
duaklir pressairNew Drug Application2022-08-01
Show 5 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J7605
Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
Clinical
Clinical Trials
562 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AsthmaD001249EFO_0000270J4523501144846273
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.92447885839248
Obstructive lung diseasesD008173HP_00065361433664226177
Lung diseasesD008171HP_0002088J98.4229553521138
EmphysemaD004646EFO_0000464J43459
BronchitisD001991J40358
Disease progressionD0184501337
Cough-variant asthmaD00009682311326
Pulmonary emphysemaD011656J43246
Chronic bronchitisD029481J42246
Show 22 more
Indications Phases 3
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients8210
Lung neoplasmsD008175HP_0100526C34.9011
Precancerous conditionsD01123011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitisD065631J30.922
RhinitisD012220EFO_0008521J3122
Chronic coughD00009682222
Personal satisfactionD01054911
Patient satisfactionD01706011
Type 1 diabetes mellitusD003922EFO_0001359E1011
HypoglycemiaD007003HP_0001943E16.211
Bronchial hyperreactivityD01653511
HypertrophyD006984EFO_000246011
ObesityD009765EFO_0001073E66.911
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameArformoterol
INNarformoterol
Description
N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide is a phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent. It is a member of phenols, a member of formamides, a secondary amino compound, a secondary alcohol and a member of phenylethanolamines.
Classification
Small molecule
Drug classbronchodilators (phenethylamine derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1
Identifiers
PDB
CAS-ID67346-49-0
RxCUI25255
ChEMBL IDCHEMBL1363
ChEBI ID408174
PubChem CID3410
DrugBankDB01274
UNII ID5ZZ84GCW8B (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRB1
Gene synonyms
ADRB1R, B1AR
NCBI Gene ID
Protein name
beta-1 adrenergic receptor
Protein synonyms
adrenergic, beta-1-, receptor, Beta-1 adrenoceptor, Beta-1 adrenoreceptor
Uniprot ID
Mouse ortholog
Adrb1 (11554)
beta-1 adrenergic receptor (P34971)
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Arformoterol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,012 documents
View more details
Safety
Black-box Warning
Black-box warning for: Foradil
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,345 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use